Acase series on aripiprazole as a safer option for females with schizophrenia spectrum disorder who are of reproductive age

Abstract

This case series explores the use of aripiprazole as a safer substitute for females of reproductive age with
schizophrenia who are suffering from galactorrhea as a result of antipsychotic treatment, mainly risperidone. The
uncomfortable side effect of galactorrhea, or the spontaneous release of breast milk, is linked to increased serum
prolactin levels brought on by some antipsychotics. Three women between the ages of thirty and forty who had
been diagnosed with schizophrenia and were taking risperidone as prescribed experienced galactorrhea. A
gynecologist started cabergoline therapy to control prolactin levels in an effort to treat galactorrhea and
schizophrenia symptoms. The patients gradually switched from risperidone to aripiprazole at the same time.
Aripiprazole successfully reduced galactorrhea, restored normal serum prolactin levels, and preserved the stability
of schizophrenia treatment during the trial. According to this case series, aripiprazole may be a good substitute for
women of reproductive age because it strikes a balance between controlling mental symptoms and reducing
unpleasant side effects. To confirm these results and investigate the wider ramifications of aripiprazole in
comparable clinical settings, more investigation is necessary.